Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Axonics(AXNX) Zacks Investment Research·2024-03-15 13:56Axonics, Inc. (AXNX) recently achieved a milestone with the CE Mark approval of its fourth-generation rechargeable Sacral Neuromodulation (SNM) system, the R20. This groundbreaking device is set to redefine the treatment landscape for bladder and bowel dysfunction, offering new hope to patients grappling with these challenging conditions.The R20 system is engineered for longevity and convenience, boasting a functional lifespan of at least 20 years within the body. This remarkable durability reduces the freq ...